{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:48:32Z","timestamp":1759366112458,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T00:00:00Z","timestamp":1590796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.nrl.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T21:31:25Z","timestamp":1594243885000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["S\u00edndrome opsoclono-mioclono: caracter\u00edsticas cl\u00ednicas, aspectos terap\u00e9uticos y factores pron\u00f3sticos en una cohorte pedi\u00e1trica espa\u00f1ola"],"prefix":"10.1016","volume":"38","author":[{"given":"V.","family":"Cantar\u00edn-Extremera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jim\u00e9nez-Legido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aguilera-Albesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hedrera-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Arrabal-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gorr\u00eda-Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mart\u00ed-Carrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Yoldi-Pedtri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sagaseta-De Il\u00fardoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gonz\u00e1lez-Guti\u00e9rrez-Solana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2020.04.025_bib0230","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fneur.2017.00468","article-title":"Demographic, clinical, and inmunologic features of 389 children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study","volume":"8","author":"Pranzatelli","year":"2017","journal-title":"Front Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2005.01.051","article-title":"Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004","volume":"228","author":"Matthay","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.nrl.2020.04.025_bib0240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","article-title":"A prospective study of the presentation and management of dancing eye syndrome \/opsoclonus \u2013 myoclonus syndrome in the United Kingdom","volume":"14","author":"Pang","year":"2010","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0245","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.braindev.2014.10.010","article-title":"A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children","volume":"37","author":"Hasegawa","year":"2015","journal-title":"Brain Dev."},{"key":"10.1016\/j.nrl.2020.04.025_bib0250","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00428-002-0747-1","article-title":"Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases","volume":"442","author":"Gambini","year":"2003","journal-title":"Virchows Arch."},{"key":"10.1016\/j.nrl.2020.04.025_bib0255","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.20573","article-title":"Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors","volume":"47","author":"Cardesa-Salzmann","year":"2006","journal-title":"Pediatr Blood Cancer."},{"key":"10.1016\/j.nrl.2020.04.025_bib0260","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.arcped.2007.04.010","article-title":"Opsoclonus-myoclonus syndrome associated with Mycoplasma pneumoniae infection","volume":"14","author":"Chemli","year":"2007","journal-title":"Arch Pediatr."},{"key":"10.1016\/j.nrl.2020.04.025_bib0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.anpedi.2013.03.008","article-title":"Acute Mycoplasma pneumoniae infection-associated opsoclonus-myoclonus-ataxia syndrome","volume":"79","author":"Huici","year":"2013","journal-title":"An Pediatr."},{"key":"10.1016\/j.nrl.2020.04.025_bib0270","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fneur.2018.00864","article-title":"Opsoclonus-Myoclonus Syndrome Associated With West-Nile Virus Infection: Case Report and Review of the Literature","volume":"9","author":"Radu","year":"2018","journal-title":"Front Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0275","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.pediatrneurol.2010.02.009","article-title":"Opsoclonus-myoclonus syndrome attributable to hepatitis C infection","volume":"42","author":"Ertekin","year":"2010","journal-title":"Pediatr Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0280","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s40064-015-1429-1","article-title":"Opsoclonus-myoclonus syndrome after adenovirus infection","volume":"4","author":"Syrbe","year":"2015","journal-title":"Springerplus."},{"key":"10.1016\/j.nrl.2020.04.025_bib0285","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/ped.12433","article-title":"Opsoclonus-myoclonus syndrome following rotavirus gastroenteritis","volume":"56","author":"Gurkas","year":"2014","journal-title":"Pediatr Int."},{"key":"10.1016\/j.nrl.2020.04.025_bib0290","series-title":"Swaiman's Pediatric Neurology: Principles and Practice.","first-page":"938","article-title":"Opsoclonus myoclonus syndrome","author":"Pranzatelli","year":"2017"},{"key":"10.1016\/j.nrl.2020.04.025_bib0295","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J Child Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0029-1237723","article-title":"Long-Term Follow-Up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"De Grandis","year":"2009","journal-title":"Neuropediatrics."},{"key":"10.1016\/j.nrl.2020.04.025_bib0305","first-page":"54","article-title":"Early Detection and Treatment of Neuroblastic Tumor with Opsoclonus-Myoclonus Syndrome Improve Neurological Outcome: A Review of Five Cases at a Single Institution in Japan","volume":"26","author":"Takama","year":"2016","journal-title":"Eur J Pediatr Surg."},{"key":"10.1016\/j.nrl.2020.04.025_bib0310","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1542\/peds.2004-2377","article-title":"Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia","volume":"116","author":"Mitchell","year":"2005","journal-title":"Pediatrics."},{"key":"10.1016\/j.nrl.2020.04.025_bib0315","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0029-1237723","article-title":"Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"De Grandis","year":"2009","journal-title":"Neuropediatrics."},{"key":"10.1016\/j.nrl.2020.04.025_bib0325","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejpn.2009.12.005","article-title":"Opsoclonus-myoclonus in children associated or not with neuroblastoma","volume":"14","author":"Krug","year":"2010","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0330","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics."},{"key":"10.1016\/j.nrl.2020.04.025_bib0335","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/0883073812471433","article-title":"Clinical profile and outcome of children with opsoclonus-myoclonus syndrome","volume":"29","author":"Singhi","year":"2014","journal-title":"J Child Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0340","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.4103\/0028-3886.241404","article-title":"Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital","volume":"66","author":"Huddar","year":"2018","journal-title":"Neurol India."},{"key":"10.1016\/j.nrl.2020.04.025_bib0345","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/s-0033-1358604","article-title":"Update on pediatric opsoclonus myoclonus syndrome","volume":"44","author":"Hero","year":"2013","journal-title":"Neuropediatrics."},{"key":"10.1016\/j.nrl.2020.04.025_bib0350","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.410350607","article-title":"Course and outcome of acute cerebellar ataxia","volume":"35","author":"Connolly","year":"1994","journal-title":"Ann Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0355","unstructured":"PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ\u00ae): Health Professional Version. National Cancer Institute (US): 2002-2019. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26389190."},{"key":"10.1016\/j.nrl.2020.04.025_bib0360","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pcl.2014.09.015","article-title":"Neuroblastoma: paradigm for precision medicine","volume":"62","author":"Irwin","year":"2015","journal-title":"Pediatr Clin North Am."},{"key":"10.1016\/j.nrl.2020.04.025_bib0365","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E","article-title":"Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group","volume":"28","author":"Russo","year":"1997","journal-title":"Med Pediatr Oncol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0370","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0929-693X(00)80129-3","article-title":"Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long term survival. Study of the French Society of Pediatric Oncologists","volume":"7","author":"Plantaz","year":"2000","journal-title":"Arch Pediatr."},{"key":"10.1016\/j.nrl.2020.04.025_bib0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/1096-911X(200008)35:2<153::AID-MPO18>3.0.CO;2-7","article-title":"False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma","volume":"35","author":"Biasotti","year":"2000","journal-title":"Med Pediatr Oncol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0380","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/B978-0-444-52910-7.00042-8","article-title":"Opsoclonus-myoclonus syndrome","volume":"112","author":"Pike","year":"2013","journal-title":"Handb Clin Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0455","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/adc.2010.204792","article-title":"Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome","volume":"97","author":"Brunklaus","year":"2012","journal-title":"C. Arch Dis Child."},{"key":"10.1016\/j.nrl.2020.04.025_bib0390","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2020.04.025_bib0395","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fimmu.2018.00557","article-title":"Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines\/Cytokines","volume":"9","author":"Pranzatelli","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0400","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.pediatrneurol.2015.07.010","article-title":"Pediatric Opsoclonus-Myoclonus-Ataxia Syndrome Associated With Anti-N-methyl-D-aspartate Receptor Encephalitis","volume":"53","author":"Player","year":"2015","journal-title":"Pediatr Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0405","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jneuroim.2018.04.007","article-title":"Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS","volume":"321","author":"Pranzatelli","year":"2018","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2014.04.009","article-title":"Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF","volume":"272","author":"DeFelipe-Mimbrera","year":"2014","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0415","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2015.11.007","article-title":"Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome","volume":"38","author":"Pranzatelli","year":"2016","journal-title":"Brain Dev."},{"key":"10.1016\/j.nrl.2020.04.025_bib0420","article-title":"Clinical and demographic features of 389 children with OMS: an International Cohort","author":"Tate","year":"2014","journal-title":"In: Proceedings of the 13th International Child Neurology Congress, Iguazu Falls, Brazil"},{"key":"10.1016\/j.nrl.2020.04.025_bib0425","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs."},{"key":"10.1016\/j.nrl.2020.04.025_bib0430","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/mds.10283","article-title":"Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG","volume":"17","author":"Pranzatelli","year":"2002","journal-title":"Mov Disord."},{"key":"10.1016\/j.nrl.2020.04.025_bib0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1542\/peds.109.1.86","article-title":"Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae","volume":"109","author":"Mitchell","year":"2002","journal-title":"Pediatrics."},{"key":"10.1016\/j.nrl.2020.04.025_bib0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pediatrneurol.2017.04.027","article-title":"Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome","volume":"73","author":"Pranzatelli","year":"2017","journal-title":"Pediatr Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0445","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J Child Neurol."},{"key":"10.1016\/j.nrl.2020.04.025_bib0450","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14737175.2016.1176914","article-title":"Dharmalingam B. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment","volume":"16","author":"Blaes","year":"2016","journal-title":"Expert Rev Neurother"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485320301377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485320301377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:14:07Z","timestamp":1759324447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485320301377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0213485320301377"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2020.04.025","relation":{},"ISSN":["0213-4853"],"issn-type":[{"type":"print","value":"0213-4853"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00edndrome opsoclono-mioclono: caracter\u00edsticas cl\u00ednicas, aspectos terap\u00e9uticos y factores pron\u00f3sticos en una cohorte pedi\u00e1trica espa\u00f1ola","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}